Hoffmann-la Roche Inc.

Other

Wendy Lea Corbett

Ramakanth Sarabu

Nancy-Ellen Haynes

Robert Francis Kester

Paige Erin Mahaney

Joseph Samuel Grimsby

George W Holland

Fred Thomas Bizzarro

Joseph Francis Grippo

Kin-Chun Thomas Luk

Steven Gregory Mischke

Jagdish Kumar Racha

Robert Lewis Crowther

Pete William Dunten

R Ursula Kammlott

Christine Maria Lukacs

Ka Wang

Li Chen

Jefferson Wright Tilley

Yi Heng Chen

Yimin Qian

Sung-Sau So

Achyutharao Sidduri

Lichun Feng

Jin-Jun Liu

Shaoqing Chen

Kevin Richard Guertin

Kshitij Chhabilbhai Thakkar

Steven Joseph Berthel

Nathan Robert Scott

Francis A Mennona

Apostolos Dermatakis

Antonio Focella

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Azaindole glucokinase activators

Crystalline forms of mammalian Glucokinase, ideally human liver isozyme source, of sufficient size and quality to obtain structural data by X-ray crystallography are presented. Methods of growing such crystals are also disclosed.

Crystals of glucokinase and methods of growing them

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Heteroaromatic glucokinase activators

The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

5-substituted-six-membered heteroaromatic glucokinase activators

Crystalline forms of mammalian Gluckokinase of sufficient size and quality to obtain structural data by X-ray crystallography are presented. Methods of growing such crystals are also disclosed.

The present invention provides glucokinase activators of formula I:wherein R, Rand Rare defined in the specification. Glucokinase activators are useful for increasing insulin secretion in the treatment of type II diabetes.

Indole-3-carboxamides as glucokinase activators

Glucokinase activating amides useful for increasing insulin secretion in the treatment of type II diabetes are disclosed.

Fused heteroaromatic glucokinase activators

Urea derivatives

Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes.

Glucokinase activating amides as herein disclosed are useful for increasing insulin secretion in the treatment of type II diabetes.

Growing community of inventors

Randolph, NJ, United States of America

Wendy Lea Corbett